Gupta Vani, Wong Andrew T, Radigan Rachel, Sahagian Michelle, Fu Sophia L, Barney Austin, Pettit Jeffrey, Shah Rishi, Singh Shridevi, Deitch Jana, Kao Johnny
The New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York.
Good Samaritan University Hospital, West Islip, New York.
Adv Radiat Oncol. 2025 Jun 22;10(9):101817. doi: 10.1016/j.adro.2025.101817. eCollection 2025 Sep.
As accelerated partial breast irradiation is gaining widespread acceptance for low-risk breast cancers treated with breast conservation, its role following oncoplastic surgery remains controversial.
We performed a prospective phase 2 trial of women aged 50 and older who were estrogen receptor positive with stage 0 to 1 breast cancer measuring ≤3 cm following successful lumpectomy with optional oncoplastic reconstruction. Patients were treated on the Varian Edge radiosurgery system to a prescribed dose of 30 Gy in 5 fractions, and the primary endpoints were feasibility and safety. Patient-reported cosmesis was assessed using the Breast Cancer Treatment Outcome Scale validated instrument.
From 2018 to 2022, 50 patients with 52 tumors with a median age of 76 were enrolled, including 79% invasive breast cancer with 48% undergoing oncoplastic reconstruction. With a median follow-up of 47 months, long-term patient-reported cosmesis was excellent in 89% of patients and good in 11% of patients. All patients were locally controlled, but there were 2 ipsilateral breast events consisting of an intramammary lymph node failure and second primary triple-negative breast cancer outside the radiation field, both successfully salvaged with further local and systemic therapy.
In carefully selected patients with low-risk early-stage breast cancer, patients treated with a 5-fraction regimen of partial breast irradiation achieve excellent cosmetic and oncological outcomes. Oncoplastic reconstruction was not a contraindication to partial breast irradiation.
随着加速部分乳腺照射在接受保乳治疗的低风险乳腺癌中得到广泛认可,其在肿瘤整形手术后的作用仍存在争议。
我们对50岁及以上、雌激素受体阳性、0至1期乳腺癌且肿瘤大小≤3 cm的女性进行了一项前瞻性2期试验,这些女性在成功进行肿块切除并可选择肿瘤整形重建后入组。患者在瓦里安Edge放射外科系统上接受治疗,处方剂量为30 Gy,分5次给予,主要终点是可行性和安全性。使用经过验证的乳腺癌治疗结果量表评估患者报告的美容效果。
2018年至2022年,共纳入50例患者的52个肿瘤,中位年龄为76岁,其中79%为浸润性乳腺癌,48%接受了肿瘤整形重建。中位随访47个月,89%的患者长期患者报告的美容效果为优,11%为良。所有患者均实现局部控制,但有2例同侧乳腺事件,包括乳腺内淋巴结失败和放疗野外的第二原发性三阴性乳腺癌,均通过进一步的局部和全身治疗成功挽救。
在精心挑选的低风险早期乳腺癌患者中,接受5次分割方案的部分乳腺照射治疗的患者可获得优异的美容和肿瘤学结果。肿瘤整形重建并非部分乳腺照射的禁忌证。